Stay updated with breaking news from Forbion growth. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pre-clinical studies demonstrated beneficial effects of SEFA-6179 in preventing the development of parenteral nutrition-induced cholestasis and liver injury associated with intestinal failure associated
Financing co-led by Ysios Capital and Forbion Growth NorthSea Therapeutics B.V., ('NST') a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis
Forbion Appoints Nanna Lüneborg as a General Partner streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Forbion Appoints Nanna Lüneborg as a General Partner globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
LaingBuisson News Sander Slootweg, managing partner and co-founder of Forbion European life sciences venture capital firm, Forbion, has announced the final close of its Forbion Growth 1 Fund at â¬360m (US$428m). The fund is focused on investing in late-stage life sciences companies, particularly European companies that develop novel therapies for areas of high medical need. The hard cap exceeds the original target size of â¬250m. Forbion uses three strategies that aim to provide: private growth capital for clinical stage development assets, cross-over capital to companies aiming to pursue a public listing in the near-term, as well as capital injections that support existing under-valued public companies. It plans to take a leading position in its targets with an investment size of up to â¬35m per deal.